RapidAI

RapidAI is a healthcare technology company that specializes in developing artificial intelligence (AI) solutions and workflow platforms for diagnosing and treating neurovascular, cardiac, and vascular diseases. Their flagship offering is the Rapid software suite, which utilizes advanced imaging analysis and machine learning algorithms to assist physicians in quickly identifying and triaging patients with conditions such as stroke, aneurysm, and pulmonary embolism.

The Rapid software leverages AI to analyze CT, MRI, and angiography scans, providing automated assessments and notifications to healthcare providers. This technology enables faster detection of conditions like intracranial hemorrhage, large vessel occlusion, and early signs of brain injury. By streamlining the diagnosis process, RapidAI's solutions aim to reduce treatment delays and improve patient outcomes.

In addition to imaging analysis, RapidAI offers platforms that facilitate coordinated care between hospital teams and emergency medical services, operational analytics for hospitals, and clinical trial support tools. Their solutions have received numerous FDA clearances, including the first-ever clearance in the computer-aided diagnostic software (CADx) category for their Rapid ASPECTS product in July 2020.

RapidAI's stroke solutions are currently utilized in over 1,800 hospitals worldwide, and the company continues to expand its offerings to address new disease states. In April 2023, they received FDA clearance for Rapid NCCT Stroke, enabling the detection of suspected intracranial hemorrhage and large vessel occlusion from non-contrast CT imaging.